The application of budesonide/formoterol (Symbicort) adjustable maintenance dosing to real-life clinical practice

Research output: Contribution to journalEditorial

Abstract

Despite effective drugs and devices, optimal asthma control is rarely achieved long term. Clinicians should consider both the therapies and management strategies employed, Adjustable maintenance dosing, where patients step-up or step-down their medication depending on symptom level, has been proposed to improve asthma control in a real-life setting. To implement adjustable maintenance dosing, patients require a Personalised Asthma Action Plan, detailing instructions agreed between patient and clinician on how they should adjust their dose in line with asthma variations to prevent deterioration in control. Several factors are necessary to achieve a clinician-agreed and supported patient-adjusted management strategy: effective therapy; patient willingness to participate in their action plan, which should not lie over-complicated to follow; adequate physician time for patient education about their disease and action plan. Results from eight studies have shown that adjustable maintenance dosing is practical and results in equal or better control with less medication use and lower costs than fixed dosing.

Original languageEnglish
Pages (from-to)42-46
Number of pages4
JournalInternational Journal of Clinical Practice
Volume58
Issue numberSUPPL 141
Publication statusPublished - Aug 2004

Keywords

  • real-life
  • budesonide/formoterol
  • asthma
  • adjustable maintenance dosing
  • GUIDED SELF-MANAGEMENT
  • ASTHMA
  • BUDESONIDE
  • EXACERBATIONS
  • MEDICATION
  • FORMOTEROL
  • MORBIDITY
  • PATIENT

Cite this

@article{c0c80544266342b68fad03d14a9d5c3d,
title = "The application of budesonide/formoterol (Symbicort) adjustable maintenance dosing to real-life clinical practice",
abstract = "Despite effective drugs and devices, optimal asthma control is rarely achieved long term. Clinicians should consider both the therapies and management strategies employed, Adjustable maintenance dosing, where patients step-up or step-down their medication depending on symptom level, has been proposed to improve asthma control in a real-life setting. To implement adjustable maintenance dosing, patients require a Personalised Asthma Action Plan, detailing instructions agreed between patient and clinician on how they should adjust their dose in line with asthma variations to prevent deterioration in control. Several factors are necessary to achieve a clinician-agreed and supported patient-adjusted management strategy: effective therapy; patient willingness to participate in their action plan, which should not lie over-complicated to follow; adequate physician time for patient education about their disease and action plan. Results from eight studies have shown that adjustable maintenance dosing is practical and results in equal or better control with less medication use and lower costs than fixed dosing.",
keywords = "real-life, budesonide/formoterol, asthma, adjustable maintenance dosing, GUIDED SELF-MANAGEMENT, ASTHMA, BUDESONIDE, EXACERBATIONS, MEDICATION, FORMOTEROL, MORBIDITY, PATIENT",
author = "Haughney, {John Andrew Francis} and Sears, {M. R.}",
year = "2004",
month = "8",
language = "English",
volume = "58",
pages = "42--46",
journal = "International Journal of Clinical Practice",
issn = "1368-5031",
publisher = "Wiley-Blackwell",
number = "SUPPL 141",

}

TY - JOUR

T1 - The application of budesonide/formoterol (Symbicort) adjustable maintenance dosing to real-life clinical practice

AU - Haughney, John Andrew Francis

AU - Sears, M. R.

PY - 2004/8

Y1 - 2004/8

N2 - Despite effective drugs and devices, optimal asthma control is rarely achieved long term. Clinicians should consider both the therapies and management strategies employed, Adjustable maintenance dosing, where patients step-up or step-down their medication depending on symptom level, has been proposed to improve asthma control in a real-life setting. To implement adjustable maintenance dosing, patients require a Personalised Asthma Action Plan, detailing instructions agreed between patient and clinician on how they should adjust their dose in line with asthma variations to prevent deterioration in control. Several factors are necessary to achieve a clinician-agreed and supported patient-adjusted management strategy: effective therapy; patient willingness to participate in their action plan, which should not lie over-complicated to follow; adequate physician time for patient education about their disease and action plan. Results from eight studies have shown that adjustable maintenance dosing is practical and results in equal or better control with less medication use and lower costs than fixed dosing.

AB - Despite effective drugs and devices, optimal asthma control is rarely achieved long term. Clinicians should consider both the therapies and management strategies employed, Adjustable maintenance dosing, where patients step-up or step-down their medication depending on symptom level, has been proposed to improve asthma control in a real-life setting. To implement adjustable maintenance dosing, patients require a Personalised Asthma Action Plan, detailing instructions agreed between patient and clinician on how they should adjust their dose in line with asthma variations to prevent deterioration in control. Several factors are necessary to achieve a clinician-agreed and supported patient-adjusted management strategy: effective therapy; patient willingness to participate in their action plan, which should not lie over-complicated to follow; adequate physician time for patient education about their disease and action plan. Results from eight studies have shown that adjustable maintenance dosing is practical and results in equal or better control with less medication use and lower costs than fixed dosing.

KW - real-life

KW - budesonide/formoterol

KW - asthma

KW - adjustable maintenance dosing

KW - GUIDED SELF-MANAGEMENT

KW - ASTHMA

KW - BUDESONIDE

KW - EXACERBATIONS

KW - MEDICATION

KW - FORMOTEROL

KW - MORBIDITY

KW - PATIENT

M3 - Editorial

VL - 58

SP - 42

EP - 46

JO - International Journal of Clinical Practice

JF - International Journal of Clinical Practice

SN - 1368-5031

IS - SUPPL 141

ER -